• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Sight Sciences Announces Appointment of Brenda Becker to Board of Directors

    3/16/22 8:00:00 AM ET
    $SGHT
    Medical/Dental Instruments
    Health Care
    Get the next $SGHT alert in real time by email

    MENLO PARK, Calif., March 16, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announced the appointment of Brenda Becker to its Board of Directors, effective March 15, 2022. As part of her duties, Ms. Becker has joined the Nominating and Governance Committee. Ms. Becker has more than 40 years of combined private and public sector experience focused on health policy and legislation. She currently serves as Senior Vice President, Global Government Affairs at Boston Scientific.

    "Brenda's four decades of public service and private sector expertise is an ideal fit for our Board of Directors, and we are extremely pleased to welcome her. We operate in a heavily regulated industry with many key constituents, including government entities such as policy and lawmakers, regulators, payors and customers," said Paul Badawi, co-founder and CEO, Sight Sciences. "Navigating the regulatory environment and ensuring appropriate access to our current and planned products in the U.S. and internationally will be crucial to our continued success. Brenda's vast experience in government and business will help us achieve our goals. In addition, she shares our dedication to fostering scientific innovation and ensuring that patients have access to breakthrough technologies. We are thrilled that Brenda has joined us on our mission to improve patients' lives and ‘Deliver the Power of Sight.'"

    Prior to joining Boston Scientific in 2007, Ms. Becker served in the George W. Bush administration under former Vice President Dick Cheney as Assistant to the Vice President for Legislative Affairs. In that capacity, she advised the Vice President and senior White House staff on legislative strategy from 2004 to 2007. In addition, Ms. Becker was nominated by President Bush and confirmed by the U.S. Senate in 2001 to serve as the Assistant Secretary for Legislative and Intergovernmental Affairs at the U.S. Department of Commerce where she provided counsel to the Secretary of Commerce and other senior commerce officials. Before entering public service, Ms. Becker held increasing roles of responsibility overseeing state and federal affairs at the Blue Cross Blue Shield Association for 20 years.

    "I share Sight Sciences' belief that innovation in eyecare products has the potential to improve patients' vision and their quality of life," said Ms. Becker. "It's an honor to join Sight Sciences' Board of Directors. I look forward to contributing toward its next stages of growth as they expand their existing businesses in glaucoma and dry eye and develop their robust pipeline of innovations in ophthalmology and optometry."

    About Sight Sciences

    Sight Sciences is an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients' lives. Using minimally invasive or non-invasive approaches to target the underlying causes of the world's most prevalent eye diseases, Sight Sciences seeks to create more effective treatment paradigms that enhance patient care and supplant conventional outdated approaches. The Company's OMNI® Surgical System is a minimally invasive glaucoma surgery (MIGS) device indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma (POAG), the world's leading cause of irreversible blindness. The Company's TearCare® System is 510(k) cleared for the application of localized heat therapy in adult patients with evaporative dry eye disease due to meibomian gland dysfunction (MGD), enabling office-based clearance of gland obstructions by an eye care professional to address the leading cause of dry eye disease. For more information, visit www.sightsciences.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"). Words such as "may," "will," "expect," "plan," "anticipate" and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Among other things, for those statements, the Company claims the protection of safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

    Media contact:

    Shay Smith

    Health+Commerce

    707.971.9779

    [email protected]

    Investor contact:

    Philip Taylor

    Gilmartin Group

    415.937.5406

    [email protected]



    Primary Logo

    Get the next $SGHT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SGHT

    DatePrice TargetRatingAnalyst
    12/6/2024$5.50Buy
    UBS
    11/4/2024$10.00 → $5.00Buy → Hold
    Lake Street
    8/21/2024$10.00Buy
    Lake Street
    9/12/2023$10.00 → $4.50Neutral → Underperform
    BofA Securities
    9/12/2023$15.00 → $5.50Overweight → Neutral
    Piper Sandler
    9/12/2023Outperform → Mkt Perform
    William Blair
    8/24/2023$12.00 → $8.40Overweight → Equal-Weight
    Morgan Stanley
    7/10/2023$15.00 → $9.00Buy → Neutral
    Citigroup
    More analyst ratings

    $SGHT
    Financials

    Live finance-specific insights

    See more
    • Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

      MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025.   Recent Financial and Business Highlights Generated first quarter 2025 total revenue of $17.5 million, a decrease of 9% compared to the same period in the prior year. This decline was primarily due to lower revenue from the Company's

      5/8/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

      MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at

      4/24/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Initiates Full Year 2025 Financial Guidance

      MENLO PARK, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the fourth quarter and full year ended December 31, 2024 and initiated financial guidance for full year 2025. Recent Financial Highlights Generated fourth quarter 2024 total revenue of $19.1 million, an increase of 2% compared to the same period in the prior year, and full year 2024 total revenue of $79.9 million, a decrease of 1% compared to full year 2023.Achieved total gross marg

      3/5/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Encrantz Staffan bought $451,734 worth of shares (128,189 units at $3.52), increasing direct ownership by 12% to 1,157,705 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/29/25 9:31:17 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • EVP, Research & Development Raheja Manohar K. bought $53,250 worth of shares (20,000 units at $2.66) and was granted 24,000 shares, increasing direct ownership by 40% to 155,000 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      3/13/25 9:51:29 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • EVP, Research & Development Raheja Manohar K. bought $19,250 worth of shares (5,000 units at $3.85), increasing direct ownership by 5% to 111,000 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      12/9/24 6:16:25 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sight Sciences to Present at the Stifel 2025 Virtual Ophthalmology Forum on May 27th

      MENLO PARK, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced plans to present at the Stifel 2025 Virtual Ophthalmology Forum. Sight Sciences' management is scheduled to present on Tuesday, May 27, 2025, at 09:00 am PT / 12:00 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the Investors section of the Company's website at https://investors.sightsciences.com/. About Sight Sciences Sight Sciences is an eyecar

      5/14/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences Reports First Quarter 2025 Financial Results and Reaffirms Full Year 2025 Revenue Guidance

      MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today reported financial results for the first quarter ended March 31, 2025, reaffirms revenue guidance for full year 2025, and announces improved adjusted operating expenses guidance for full year 2025.   Recent Financial and Business Highlights Generated first quarter 2025 total revenue of $17.5 million, a decrease of 9% compared to the same period in the prior year. This decline was primarily due to lower revenue from the Company's

      5/8/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

      MENLO PARK, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced it will report financial results for the first quarter ended March 31, 2025, after the market close on Thursday, May 8, 2025. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at

      4/24/25 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Encrantz Staffan bought $451,734 worth of shares (128,189 units at $3.52), increasing direct ownership by 12% to 1,157,705 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/29/25 9:31:17 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • EVP, Research & Development Raheja Manohar K. was granted 12,767 shares, increasing direct ownership by 8% to 167,767 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/21/25 8:39:13 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Chief Financial Officer Bauerlein Alison sold $45,430 worth of shares (13,066 units at $3.48), decreasing direct ownership by 2% to 636,728 units (SEC Form 4)

      4 - Sight Sciences, Inc. (0001531177) (Issuer)

      5/21/25 8:38:03 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    SEC Filings

    See more
    • SEC Form SD filed by Sight Sciences Inc.

      SD - Sight Sciences, Inc. (0001531177) (Filer)

      5/30/25 4:35:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • SEC Form 10-Q filed by Sight Sciences Inc.

      10-Q - Sight Sciences, Inc. (0001531177) (Filer)

      5/8/25 4:16:05 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Sight Sciences, Inc. (0001531177) (Filer)

      5/8/25 4:08:25 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care

    $SGHT
    Leadership Updates

    Live Leadership Updates

    See more

    $SGHT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $SGHT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Sight Sciences Appoints Gary Burbach to its Board of Directors

      MENLO PARK, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) (Sight Sciences, or the Company), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that Gerhard (Gary) F. Burbach was appointed to the Company's Board of Directors on April 21, 2025. Mr. Burbach will serve as a Class II director with a term expiring at the 2026 Annual Meeting of Stockholders. "We are very excited to add Gary to our Board of Directors," stated Paul Badawi, Co-founder and Chief Executive Officer of Sight Sciences. "He brings a strong medtech industry background with a pro

      4/22/25 4:05:00 PM ET
      $BWXT
      $SGHT
      Industrial Machinery/Components
      Industrials
      Medical/Dental Instruments
      Health Care
    • Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

      MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today the appointment of MK Raheja, Ph.D. as its Executive Vice President, Research and Development, and Brenton Taylor as its Executive Vice President, Operations, effective November 4, 2024. Sight Sciences also announced that Sam Park, its Chief Operating Officer, who oversaw both R&D and Operations, will be retiring from his role at the Company effective November 15, 2024, and will remain available as a con

      11/7/24 4:04:00 PM ET
      $INGN
      $SGHT
      Industrial Specialties
      Health Care
      Medical/Dental Instruments
    • Sight Sciences Appoints Matt Link as Chief Commercial Officer

      MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced the appointment of Matthew Link as its Chief Commercial Officer, effective September 11, 2023. "We are very excited to have Matt join Sight Sciences as we scale our Surgical Glaucoma and Dry Eye businesses. Matt is a highly talented medtech business leader with a track record of success in transforming treatment paradigms with disruptive new technology, and predictably scaling in a public high-growth

      9/11/23 4:05:00 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • UBS initiated coverage on Sight Sciences with a new price target

      UBS initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $5.50

      12/6/24 8:14:13 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Sight Sciences downgraded by Lake Street with a new price target

      Lake Street downgraded Sight Sciences from Buy to Hold and set a new price target of $5.00 from $10.00 previously

      11/4/24 8:26:06 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Lake Street initiated coverage on Sight Sciences with a new price target

      Lake Street initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $10.00

      8/21/24 8:27:48 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sight Sciences Inc.

      SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

      11/14/24 11:57:36 AM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G/A filed by Sight Sciences Inc. (Amendment)

      SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)

      2/14/24 5:24:02 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Sight Sciences Inc.

      SC 13G - Sight Sciences, Inc. (0001531177) (Subject)

      2/13/24 6:52:37 PM ET
      $SGHT
      Medical/Dental Instruments
      Health Care